The agreement among the Reporting Persons relating to the joint filing of this
Schedule 13D is filed as Exhibit 99.5 hereto.
None of the Reporting Persons, or to the knowledge of the Reporting Persons, any
person listed on Annex A hereto, has, during the last five years: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities
laws or finding any violation with respect to such laws.
Please see Annex A for information regarding the directors and executive
officers of CBI.
As a result of CBIs relationships with the other Reporting Persons, it is possible that CBI may be deemed a member
of a group, within the meaning of Rule 13d-5(b)(1) under Act, with such other Reporting Persons. CBI is making this filing as a precautionary matter and this filing shall not be deemed an admission
that CBI is a member of a group or is subject to the reporting requirements of Section 13 of the Act.
Item 4 Purpose of Transaction
The disclosure in Item 4 is hereby amended and restated in its entirety to read as follows:
The Reporting Persons who hold Common Stock directly acquired those shares as an investment in the regular course of their businesses. The
Reporting Persons may engage in discussions with management, the Issuers board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future
plans of the Issuer. The Reporting Persons intend to re-examine their investment from time to time and, depending on prevailing market conditions, other investment opportunities, liquidity requirements or
other investment considerations the Reporting Persons deem material, the Reporting Persons may from time to time acquire additional Common Stock in the open market, block trades, negotiated transactions, or otherwise. The Reporting Persons may also
dispose of all or a portion of the Issuers securities, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Issuers Common Stock, in each
case, subject to limitations under applicable law. The Reporting Persons intend to continue to actively consider additional dispositions of the Issuers Common Stock, subject to market conditions, in light of the Issuers proposed
transaction with BioNTech SE.
The Reporting Persons have not yet determined which, if any, of the above courses of action they may
ultimately take. The Reporting Persons future actions with regard to the Issuer are dependent on their evaluation of the factors listed above, circumstances affecting the Issuer in the future, including prospects of the Issuer, general market
and economic conditions and other factors deemed relevant. The Reporting Persons reserve the right to determine in the future whether to change the purpose or purposes described above or whether to adopt plans or proposals of the type specified
above or otherwise.
Except as set forth above, the Reporting Persons have no plans or proposals with respect to the Issuer.
Item 5 Interest in Securities of the Issuer
The disclosure in Item 5 is hereby amended and restated in its entirety to read as follows:
(a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D
that relate to the aggregate number and percentage of common stock (including but not limited to footnotes to such information) are incorporated herein by reference.
The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the
number of common stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited
to footnotes to such information) are incorporated herein by reference.
1,729,556 shares of Common Stock are owned directly by AIH and may
be deemed to be beneficially owned by Access LLC, AIM and Len Blavatnik because (i) Access LLC holds a majority of the outstanding voting interests in AIH, (ii) AIM controls Access LLC and AIH, and (iii) Len Blavatnik controls AIM and
Access LLC. Each of the Reporting Persons (other than AIH), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.